Poseida Therapeutics Inc. (PSTX)
NASDAQ: PSTX
· Real-Time Price · USD
9.50
0.00 (0.00%)
At close: Jan 07, 2025, 9:00 PM
0.00% (1D)
| Bid | 9.53 |
| Market Cap | 925.93M |
| Revenue (ttm) | 150.86M |
| Net Income (ttm) | -59.4M |
| EPS (ttm) | -0.63 |
| PE Ratio (ttm) | -15.079365079365079 |
| Forward PE | n/a |
| Analyst | Hold |
| Ask | 9.55 |
| Volume | 21,344,052 |
| Avg. Volume (20D) | 1,798,028 |
| Open | 9.58 |
| Previous Close | 9.50 |
| Day's Range | 9.50 - 9.58 |
| 52-Week Range | 1.87 - 9.67 |
| Beta | 0.54 |
About PSTX
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol PSTX
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for PSTX stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock ForecastsNext Earnings Release
Poseida Therapeutics Inc. is scheduled to release its earnings on Mar 6, 2025,
during market hours.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
5 months ago
Poseida Therapeutics shares are trading higher aft...
Unlock content with
Pro Subscription
6 months ago
Poseida Therapeutics shares are trading higher after the company reported better-than-expected Q3 financial results.
4 months ago · proactiveinvestors.com
Roche set to finalise $1.5bn Poseida Therapeutics takeoverSwiss healthcare firm Roche has said its US$1.5 billion takeover of US biopharmaceutical company Poseida Therapeutics will be completed on Wednesday. Roche on Wednesday said it had been accepted for p...
